FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective
Publication date
2023-05
Authors
Verger, Antoine
Yakushev, Igor
Albert, Nathalie L
van Berckel, Bart
Brendel, Matthias
Cecchin, Diego
Fernandez, Pablo Aguiar
Fraioli, Francesco
Guedj, Eric
Morbelli, Silvia
Editors
Advisors
Supervisors
Document Type
Editorial
Metadata
Show full item recordCollections
License
cc_by
Abstract
Keywords
Alzheimer Disease/diagnostic imaging, Amyloid, Amyloid beta-Peptides, Humans, Neuroimaging, Positron-Emission Tomography, Editorial, Comment
Citation
Verger, A, Yakushev, I, Albert, N L, van Berckel, B, Brendel, M, Cecchin, D, Fernandez, P A, Fraioli, F, Guedj, E, Morbelli, S, Tolboom, N, Traub-Weidinger, T, Van Weehaeghe, D & Barthel, H 2023, 'FDA approval of lecanemab : the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 6, pp. 1553-1555. https://doi.org/10.1007/s00259-023-06177-5